Abbott and Dexcom,two leaders in the continuous glucose monitor market,today struck a settlement agreement for ongoing patent litigation.

雅培和Dexcom這兩家連續(xù)血糖監(jiān)測儀市場的領(lǐng)先企業(yè)今天就正在進行的專利訴訟達成了和解協(xié)議。

Our sibling site,Drug Delivery Business News,reports today that the companies settled all outstanding patent disputes between them.

我們的兄弟網(wǎng)站Drug Delivery Business News今天報道說，這兩家公司解決了它們之間所有懸而未決的專利糾紛

The patent litigation relates to the companies’continuous glucose monitor(CGM)technologies.The companies and Dexcom are two leaders in the CGM space.They offer market-leading platforms,with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing their latest-generation technologies.

專利訴訟與兩家公司的連續(xù)血糖監(jiān)測儀(CGM)技術(shù)有關(guān)。這兩家公司和Dexcom是CGM領(lǐng)域的兩大領(lǐng)軍企業(yè)。它們提供市場領(lǐng)先的平臺，雅培的FreeStyle Libre 3和Dexcom的G7代表了它們最新一代的技術(shù)。

News of the settlement comes within a few weeks of a Unified Patent Court decision that sided with Abbott following a CGM patent infringement claim from Dexcom.Dexcom requested that the court find infringement with the LibrelinkUp remote analyte monitoring system.The court revoked EP282 in its entirety across the contracting member states in Europe as specified by Abbott’s request.It dismissed all of Dexcom’s infringement claims based on the patent at issue.

在Dexcom提出CGM專利侵權(quán)索賠后的幾周內(nèi)，統(tǒng)一專利法院做出了支持雅培的判決，雅培與Dexcom達成和解的消息不脛而走。Dexcom要求法院認定LibrelinkUp遠程分析監(jiān)測系統(tǒng)侵權(quán)。法院根據(jù)雅培的請求，在歐洲各簽約成員國全面撤銷了EP282。法院駁回了Dexcom基于涉案專利提出的所有侵權(quán)索賠。